ECTRIMS 2022 | Role of imaging biomarkers of myelin repair in the development of neuroprotective drugs

Cristina Granziera, MD, PhD, University Hospital of Basel, Basel, Switzerland, describes the importance of identifying imaging biomarkers of myelin repair to the development of neuroprotective and reparative drugs for the treatment of multiple sclerosis (MS). The successful development of novel drugs requires the use of appropriate biomarkers to assess the efficacy of the treatment. Hence it is a fundamental step to develop specific biomarkers to measure the desired effect of a drug. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.